• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

识别癌症中的可操作变异——双网络和批量处理工具 MTB-Report。

Identifying Actionable Variants in Cancer - The Dual Web and Batch Processing Tool MTB-Report.

机构信息

Dept. of Medical Bioinformatics, University Medical Center Göttingen, Germany.

MARGenomics, Hospital del Mar Medical Research Institute (IMIM), Spain.

出版信息

Stud Health Technol Inform. 2022 Aug 17;296:73-80. doi: 10.3233/SHTI220806.

DOI:10.3233/SHTI220806
PMID:36073491
Abstract

Next-generation sequencing methods continuously provide clinicians and researchers in precision oncology with growing numbers of genomic variants found in cancer. However, manually interpreting the list of variants to identify reliable targets is an inefficient and cumbersome process that does not scale with the increasing number of cases. Support by computer systems is needed for the analysis of large scale experiments and clinical studies to identify new targets and therapies, and user-friendly applications are needed in molecular tumor boards to support clinicians in their decision-making processes. The MTB-Report tool annotates, filters and sorts genetic variants with information from public databases, providing evidence on actionable variants in both scenarios. A web interface supports medical doctors in the tumor board, and a command line mode allows batch processing of large datasets. The MTB-Report tool is available as an R implementation as well as a Docker image to provide a tool that runs out-of-the-box. Moreover, containerization ensures a stable application that delivers reproducible results over time. A public version of the web interface is available at: http://mtb.bioinf.med.uni-goettingen.de/mtb-report.

摘要

下一代测序方法不断为精准肿瘤学的临床医生和研究人员提供越来越多在癌症中发现的基因组变异。然而,手动解释变异列表以识别可靠的靶标是一个效率低下且繁琐的过程,无法适应越来越多的病例。需要计算机系统来分析大规模实验和临床研究,以识别新的靶标和疗法,并且需要用户友好的应用程序在分子肿瘤委员会中支持临床医生的决策过程。MTB-Report 工具使用来自公共数据库的信息注释、过滤和排序遗传变异,为这两种情况下的可操作变异提供证据。一个 Web 界面支持肿瘤委员会中的医生,命令行模式允许对大型数据集进行批处理。MTB-Report 工具作为 R 实现和 Docker 镜像提供,以提供开箱即用的工具。此外,容器化确保了应用程序的稳定性,随着时间的推移提供可重复的结果。Web 界面的公共版本可在:http://mtb.bioinf.med.uni-goettingen.de/mtb-report 获得。

相似文献

1
Identifying Actionable Variants in Cancer - The Dual Web and Batch Processing Tool MTB-Report.识别癌症中的可操作变异——双网络和批量处理工具 MTB-Report。
Stud Health Technol Inform. 2022 Aug 17;296:73-80. doi: 10.3233/SHTI220806.
2
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.从体细胞变异到精准肿瘤学:分子肿瘤委员会中基于证据的治疗选择报告。
Genome Med. 2018 Mar 15;10(1):18. doi: 10.1186/s13073-018-0529-2.
3
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.晚期癌症患者使用下一代测序和分子肿瘤委员会的建议:来自 KSMO 和 KCSG 精准医学网络小组的报告。
Cancer Res Treat. 2022 Jan;54(1):1-9. doi: 10.4143/crt.2021.1115. Epub 2021 Dec 13.
4
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.分子肿瘤学委员会的实施:对在达特茅斯-希区柯克医疗中心评估的35例患者治疗决策的影响。
Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.
5
Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.在区域层面实施分子肿瘤委员会,以改善获得靶向治疗的机会。
Int J Clin Oncol. 2020 Jul;25(7):1234-1241. doi: 10.1007/s10147-020-01661-6. Epub 2020 Mar 25.
6
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.高维分子数据可重复性临床解读的可行性和结果:两个分子肿瘤委员会的比较。
BMC Med. 2022 Oct 24;20(1):367. doi: 10.1186/s12916-022-02560-5.
7
Cruxome: a powerful tool for annotating, interpreting and reporting genetic variants.Cruxome:注释、解释和报告遗传变异的有力工具。
BMC Genomics. 2021 Jun 3;22(1):407. doi: 10.1186/s12864-021-07728-6.
8
Predicting the Effect of Variants of Unknown Significance in Molecular Tumor Boards with the VUS-Predict Pipeline.使用 VUS-Predict 管道预测分子肿瘤委员会中未知意义变异的影响。
Stud Health Technol Inform. 2021 Sep 21;283:209-216. doi: 10.3233/SHTI210562.
9
Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.国家癌症研究所指定综合癌症中心实施和跟踪分子肿瘤委员会的框架。
Oncologist. 2021 Nov;26(11):e1962-e1970. doi: 10.1002/onco.13936. Epub 2021 Sep 8.
10
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.分子肿瘤委员会作为将分子数据转化为实际患者护理的临床工具。
JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067.

引用本文的文献

1
Onkopus: precise interpretation and prioritization of sequence variants for biomedical research and precision medicine.Onkopus:用于生物医学研究和精准医学的序列变异的精确解读与优先级排序
Nucleic Acids Res. 2025 Jul 7;53(W1):W431-W439. doi: 10.1093/nar/gkaf376.
2
Advancing personalized cancer therapy: Onko_DrugCombScreen-a novel Shiny app for precision drug combination screening.推进个性化癌症治疗:Onko_DrugCombScreen——一款用于精准药物联合筛选的新型Shiny应用程序。
NAR Genom Bioinform. 2025 Jan 31;7(1):lqaf004. doi: 10.1093/nargab/lqaf004. eCollection 2025 Mar.
3
Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.
助力个性化肿瘤学:分子肿瘤委员会数字支持与可视化工具的发展
BMC Med Inform Decis Mak. 2025 Jan 16;25(1):29. doi: 10.1186/s12911-024-02821-8.
4
Unveiling the Digital Evolution of Molecular Tumor Boards.揭示分子肿瘤委员会的数字化演变
Target Oncol. 2025 Jan;20(1):27-43. doi: 10.1007/s11523-024-01109-1. Epub 2024 Nov 28.
5
SeqCAT: Sequence Conversion and Analysis Toolbox.SeqCAT:序列转换与分析工具箱。
Nucleic Acids Res. 2024 Jul 5;52(W1):W116-W120. doi: 10.1093/nar/gkae422.
6
PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data.PanDrugs2:利用整合的个体多组学数据对癌症疗法进行优先级排序。
Nucleic Acids Res. 2023 Jul 5;51(W1):W411-W418. doi: 10.1093/nar/gkad412.